2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1126

Gout and Chronic Pain in Older Adults: A Medicare Claims Study
Abstract Number: 2226

Gout and the Risk of Incident Dementia in the Elderly: A Medicare Claims Study
Abstract Number: 1298

Gout and the Risk of Parkinson’s Disease in Older Adults: A Study of U.S. Medicare Data
Abstract Number: 2220

Gout, Flares and Allopurinol Use: A Population Based Study
Abstract Number: 944

Gout: A Potential Risk Factor for Uveitis in the Older Adults?
Abstract Number: 2289

Granulomatous Myositis: Heterogeneity and Response to Treatment
Abstract Number: 1818

Greater BMD Gains with Denosumab Vs Risedronate in Glucocorticoid-Treated Subjects: Results from the Final 24-Month Analysis of a Randomized, Double-Blind, Double-Dummy Study
Abstract Number: 2518

GS-9876, a Novel, Highly Selective, SYK Inhibitor in Patients with Active Rheumatoid Arthritis: Safety, Tolerability and Efficacy Results of a Phase 2 Study
Abstract Number: 990

Guanylate Binding Protein 5 (GBP5) Inhibits Rheumatoid Arthritis Synovial Fibroblast Mediated Inflammation and Tissue Destruction
Abstract Number: 1251

Guideline Adherence for Perioperative Use of Immunosuppressive Medications in Patients with Rheumatologic Disease
Abstract Number: 1828

Gut-Joint T Cell Trafficking in a Model of Bacteria-Driven Murine IBD-Spa
Abstract Number: 608

Half Dose Reduction of Methotrexate in Patient with RA Who Achieved Clinical Remission
Abstract Number: 2730

Handgrip Strength Predicts the Risk of Bone Fracture and Severe Adverse Events in Patients with Systemic Necrotizing Vasculitis
Abstract Number: 271

Health Care Disparities for Infectious and Non-Infectious Uveitis in the US
Abstract Number: 967

Health Care Utilization for Musculoskeletal Issues during the Pre-Diagnosis Period in Psoriatic Arthritis – a Population-Based Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].